胸腺法新对结直肠癌术后化疗患者免疫功能及生活质量的影响
[摘要] 目的 探讨胸腺法新对结直肠癌术后化疗患者免疫功能及生活质量的影响。 方法 2009年5月～2014年7月间结直肠癌术后患者81例在本院行化疗，其中40例患者接受化疗同时接受胸腺法新1.6 mg 皮下注射，一周2次，直到化疗结束（联合组），其余 41例患者仅接受化疗（对照组）。比较两组患者细胞免疫及生活质量。 结果 联合组在化疗第3个月开始CD4+% 明显高于对照组（P<0.05）；联合组在化疗第2个月开始CD8+%明显低于对照组（P<0.05）；联合组在化疗第2个月开始CD4+/CD8+明显高于对照组（P<0.05）。联合组在化疗第3个月开始KPS评分明显高于对照组（P<0.05）。 结论 胸腺法新能明显提高结直肠癌术后化疗患者的免疫功能及生活质量。
[关键词] 结肠癌；化疗；免疫功能；直肠癌；生活质量
[中图分类号] R735.37 [文献标识码] B [文章编号] 1673-9701（2018）06-0082-04
[Abstract] Objective To investigate the effect of thymalfasin on immune function and quality of life in patients of colorectal cancer with postoperative chemotherapy. Methods From May 2009 to July 2014， 81 patients with colorectal cancer undergoing postoperative chemotherapy in our hospital were selected. 40 patients underwent chemotherapy combined with 1.6 mg subcutaneous injection of thymalfasin twice a week until chemotherapy was completed （the combined group）. The remaining 41 patients received chemotherapy alone（the control group）. The cellular immunity and quality of life of the two groups were compared. Results The CD4+% in the combined group was significantly higher than the control group at the third month of chemotherapy（P<0.05）. The combined group had a significantly lower level of CD8+% than the control group at the second month of chemotherapy（P<0.05）. CD4+/CD8+ in the second month was significantly higher than the control group （P<0.05）. The KPS score of the combined group at the third month was significantly higher than the control group（P<0.05）....
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
